



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :

A61K 31/52, C07D 473/10, 473/04

A1

(11) International Publication Number:

WO 96/20710

(43) International Publication Date:

11 July 1996 (11.07.96)

(21) International Application Number: PCT/US95/16521

(22) International Filing Date: 18 December 1995 (18.12.95)

(30) Priority Data:

08/367,102

29 December 1994 (29.12.94)

US

08/482,551

7 June 1995 (07.06.95)

US

(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US).

(72) Inventors: CARSON, Dennis, A.; 14824 Vista Del Oceano, Del Mar, CA 92014 (US). COTTAM, Howard, B.; 208 White Horse Lane, Fallbrook, CA 92028 (US). WASSON, D., Bruce; 935 Beryl Street #1, San Diego, CA 92109 (US).

(74) Agent: BERLINER, Robert; Robbins, Berliner & Carson, 5th floor, 201 N. Figueroa Street, Los Angeles, CA 90012-2628 (US).

(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION

(57) Abstract

Novel, heterocyclic compounds having at least one ring nitrogen, disclosed side chains and, in some embodiments, an oxygen *ortho* to the ring nitrogen inhibit inflammatory responses associated with TNF- α and fibroblast proliferation *in vivo* and *in vitro*. The compounds of the invention neither appreciably inhibit the activity of cAMP phosphodiesterase nor the hydrolysis of phosphatidic acid, and are neither cytotoxic nor cytostatic. Preferred compounds of the invention are esters. Methods for the use of the novel compounds to inhibit ceramide-mediated intracellular responses to stimuli *in vivo* (particularly TNF- α) are also described. The methods are expected to be of use in reducing inflammatory responses (for example, after angioplasty), in limiting fibrosis (for example, of the liver in cirrhosis), in inhibiting cell senescence, cell apoptosis and UV induced cutaneous immune suppression.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION

RELATED PATENT APPLICATIONS

This application is a continuation-in-part of US Patent Application Serial Number
5 08/367,102, filed December 29, 1994.

STATEMENT OF GOVERNMENT SUPPORT

This invention may have been made with government support under Grant No. GM-23200 awarded by the National Institutes of Health. The government may have certain rights in the invention.

10 BACKGROUND OF THE INVENTION

1. Field of the Invention.

The invention relates to compounds effective in modulating cellular responses stimulated by ceramide-mediated signal transduction, in particular in response to stimulus by the cytokine tumor necrosis factor α (TNF- α). More specifically, it relates to compounds
15 which inhibit the development of conditions associated with cell stimulus through the ceramide-mediated signal transduction pathway.

2. History of the Prior Art.

The sphingomyelin pathway is a cellular signal transduction pathway that is believed to be involved in mediating cellular responses to several cytokines (including TNF- α and
20 IL-1 β) and growth factors (e.g., platelet derived growth factor and fibroblast growth factor) (see, e.g., Dressler, *et al.*, *Science*, 259:1715-1718, 1992; and, Jacobs and Kester, *Amer.J.Physiol.*, 265: 740-747, 1993). It is believed that interaction of such molecules with cell surface receptors triggers activation of a plasma membrane sphingomyelinase. Sphingomyelinase in turn catalyzes the hydrolysis of sphingomyelin to ceramide and
25 phosphocholine. Ceramide is believed to act as a second messenger through activation of a proline-directed, serine/threonine kinase (ceramide-activated protein kinase or "CaPK"). Ceramide also interacts with MAP kinase and protein kinase C zeta (see, e.g.,

-2-

Rivas, *et al.*, *Blood*, 83:2191-2197, 1993) and with a serine/threonine protein phosphatase (see, Hannun, *et al.*, *TIBS*, 20:73-77, 1995).

Recent investigation has provided evidence that the sphingomyelin pathway may mediate cellular senescence and apoptosis (programmed cell death) in response to TNF- α (see,
5 e.g., Jayadev, *et al.*, *J.Biol.Chem.*, 270:2047-2052, 1994; and, Dbaibo, *et al.*,
J.Biol.Chem., 268:17762-17766, 1993) and radiation (Haimovitz-Friedman, *et al.*,
J.Exp.Med., 180:525-535, 1994). In this respect, ceramide has been presumed to mimic
the effects of TNF- α on intracellular processes.

SUMMARY OF THE INVENTION

10 The invention is directed toward the development and use of compounds to inhibit
cellular responses to ceramide metabolites of the sphingomyelin signal transduction
pathway, such as inflammation, fibrosis, ultraviolet light induced cutaneous immune
suppression, cell senescence and apoptosis.

In one aspect, the invention consists of novel compounds comprised of heterocyclic
15 molecules with biologically active side chains (the "compounds of the invention").
Purine, pteridine, thiadiazolopyrimidine, quinalozine and isoquinolone based compounds
are included in the invention.

The compounds of the invention do not inhibit the activity of cAMP phosphodiesterase
and therefore do not pose the risk of side-effects associated with other TNF- α inhibitors
20 (e.g., pentoxifylline), such as sleeplessness and anxiety. Indeed, surprisingly, one of the
more potent TNF- α activity inhibitors among the compounds of the invention
(compound 37) had the least inhibitory effect on phosphodiesterase type IV, the
predominant phosphodiesterase isoenzyme in monocytes and neutrophils. This is due
to the fact that compounds such as 37 do not have a methylxanthine structure. Many
25 common phosphodiesterase inhibitors (such as theophylline, theobromine, and caffeine)
are methylxanthine compounds.

Moreover, all of the compounds of the invention inhibit apoptosis and retard cellular responses to TNF- α *in vitro* and *in vivo* with greater potency than pentoxifylline. Unexpectedly, the potency of at least the non-isoquinolone compounds appears to be dependent in part on the presence of ring nitrogens (other than the pyrimidine
5 nitrogens), suggesting that binding to the target receptor responsible for inhibition of the activity of TNF- α observed is also regulated to some extent by the presence of such ring nitrogens. Further, the effects of all of the compounds appear to be totally unrelated to phosphodiesterase inhibition. This is particularly interesting given that increases in cAMP levels in cells can induce apoptosis in B cells (see, e.g., Lømo, *et al.*, *J.*
10 *Immunol.*, 154:1634-1643, 1995).

Another aspect of the invention consists of methods for the use of the novel compounds in inhibiting ceramide-activated cellular responses to stimuli, in particular stimuli for cell senescence and apoptosis. This aspect of the invention has potential therapeutic significance in the treatment of cell-death associated conditions such as stroke, cardiac
15 ischemia, nerve damage and Alzheimer's disease.

Another aspect of the invention consists of methods which exploit the ability of the compounds of the invention to absorb UV radiation. This aspect of the invention has potential therapeutic significance in the treatment and prevention of radiation dermatoses, including those associated with therapeutic regimes for treatment of cancer.

20 The compounds of the invention are expected to be particularly useful in reducing the effects of aging in skin as well as the onset and progression of radiation dermatitis.

Further advantages and embodiments of the invention included therein will become apparent from the following disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 is a bar graph depicting inhibition of cell growth arrest in 3T3 fibroblasts according to the invention after growth arrest was induced through deprivation of the cells of serum. The cells were incubated and grown to 90% confluence in serum. The medium was then removed and replaced with serum-free medium. To assess the effect of an inventive compound (no. 37, a pteridine) on cell senescence in the presence of ceramide, aliquots of the cells were incubated with different concentrations of each. Concentrations of compound no. 37 are indicated by the insert legend while concentrations of ceramide are indicated along the x axis. Inhibitory effects were assessed as a measure of DNA synthesis; [^3H] thymidine incorporation detection is indicated along the y axis.

FIGURE 2 is a bar graph depicting inhibition of cell apoptosis in human (Jurkat) T lymphocytes according to the invention. The inhibitory activity of two inventive compounds (nos. 37 and 6 (a purine)) was tested in comparison to like activity of pentoxifylline and a control compound, Ro 20-1724. Activation of the sphingomyelin signal transduction pathway was stimulated by incubation of the cells with an anti-FAS monoclonal antibody (which binds CD95, a cell surface receptor which triggers cell apoptosis). Percent inhibition was measured as a function of the number of cells which excluded vital dye erythrosin B. Percent inhibition is indicated along the y axis while the concentration of compounds tested is indicated along the x axis.

FIGURE 3 is a bar graph depicting inhibition of activity on the part of CaPK in Jurkat cells according to the invention. The inhibitory activity of a compound of the invention (no. 37) was tested in the presence of either ceramide or anti-FAS. Inhibition of CaPK activity was measured as a function of phosphorylation and detected by autoradiography. The compounds the cells were incubated in are indicated along the y axis while the percent control (i.e., inhibition of CaPK) is indicated along the x axis. Shorter bars indicate greater relative inhibition.

-5-

FIGURE 4 (a)-(c) are copies of spectragraphs indicative of absorbance of inventive compounds no. 37, no. 6, no.37 in combination with no. 6, oxo variants of nos. 37 and 6, as well as, for comparison, PABA (p-amino benzoic acid, a common sunscreen additive) and isoquinolone. The inventive compounds absorbed through most of the UVB wavelength, while a mixture of compound nos. 37 and 6 absorbed throughout the UVB wavelength..

FIGURE 5(a) and (b) depict, respectively, the results of an enzyme-linked immunosorbent assay (ELISA) for TNF- α production by bacterial lipopolysaccharide (endotoxin) stimulated human monocytes incubated with the compounds of the invention and a control compound (RO-1724, that is a known and specific inhibitor of phosphodiesterase type IV [the predominant isoform of phosphodiesterase found in monocytes and neutrophils]). Compounds tested are identified by the number assigned to them in Table 1. The horizontal axis of each graph shows the amount of each compound tested (in μ M) while the vertical axis shows the IC₅₀ values for TNF- α production as a percentage of the production in the presence of only the control compound.

FIGURE 6 is a bar graph depicting the results of an ELISA assay for inhibition of the activity of phosphodiesterase type IV by the control compound (Ro 20-1724) and several of the inventive compounds. The horizontal axis identifies the degree of inhibition achieved in pmol substrate/minutes of contact/mg of phosphodiesterase type IV. The amounts of each compound tested are identified along the vertical axis. Compounds tested are identified by the number assigned to them in Table 1.

FIGURE 7 is a graph depicting the results of an assay for in vivo leukopenia in mouse blood in response to lipopolysaccharide (LPS). Leukopenia induced by LPS is mediated by TNF. Hence, this model assesses both TNF production and action. Compounds tested for inhibition of leukopenia are identified by the number assigned to them in Table 1. Along the x axis of the graph, the numbers correspond to the number of white blood cells detected as cells/ml of fluid. The results (shown by bars) are expressed in terms of a percentage of the leukopenia response (based on neutrophil content) to pure LPS, in absence of other compounds.

FIGURE 8 depicts the results of an assay for inhibition by compounds of the invention (nos. 37 and 6) of the effects of a cell permeable ceramide analog (C_2 - ceramide), dihydro ceramide and diacyl glycerol on TNF- α production by human monocytes. Inhibition of TNF- α production was measured by ELISA; the results are indicated in
5 pg/ml of TNF- α along the x axis.

FIGURE 9 depicts the results of an assay for inhibition by a compound of the invention (no. 37) to prevent the stimulatory effects of C_2 - ceramide or protein kinase C activity in human lymphocyte extracts. Inhibitory effects were assessed as a measure of DNA synthesis; [3H] thymidine incorporation detection is indicated along the y axis.

- 10 FIGURE 10 depicts the results of an assay for *in vitro* TNF- α production by human macrophages in response to lipopolysaccharide (LPS) and inhibition of that production by pteridine and isoquinolone compounds of the invention (nos. 37 and 11-49). Along the x axis of the graph, the numbers correspond to the concentration of TNF- α detected in pg/ml.
- 15 FIGURE 11 depicts inhibition of PDGF induced fibroblast proliferation among 3T3 fibroblasts in response to the inventive compounds. The compounds tested are identified along the x axis by the numbers assigned to them in Table 1. Inhibitory effects were assessed as a measure of DNA synthesis; [3H] thymidine incorporation detection is indicated along the y axis.
- 20 FIGURE 12 depicts inhibition of EGF induced fibroblast proliferation among 3T3 fibroblasts in response to the inventive compounds. The compounds tested are identified along the x axis by the numbers assigned to them in Table 1. Inhibitory effects were assessed as a measure of DNA synthesis; [3H] thymidine incorporation detection is indicated along the y axis.

-7-

FIGURE 13 depicts data indicative of the apoptotic protective characteristics of the compounds of the invention as represented by compounds 1C-261 and 11-49. Human lymphocytes were cultured in serum aliquots with the concentrations of the inventive compounds indicated along the x axis of the FIGURE. Protective effects were measured
5 over 4 days as a function of the length of survival of the cultured cells in the presence of the inventive compounds as compared to survival of the cells in the absence of the inventive compounds. 100% survival (y axis) means that a number of treated cells all survived throughout the test period while an equal number of untreated cells died.

FIGURE 14 shows the structure of commercially available isoquinoline structures whose
10 inhibitory effect with respect to production of TNF- α by human monocytes prior to modification to add side chain substituents according to the invention was tested. Except for Compound S52,626-6 (6,7-dimethoxy-1(2H)-isoquinoline, which possessed mild inhibitory activity as shown in FIGURE 10) none of the tested compounds possessed
15 any such inhibitory activity prior to their modification according to the invention, even at concentrations up to 500 μ M.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

I. Compounds of the Invention.

- The compounds of the invention generally comprise purines, pteridines, thiadiazolopyrimidines and quinazolines prepared according to the schemes described
- 5 below. For reference, the techniques used in synthesizing the compounds are adaptations of the well-known Traube Synthesis protocol (Lister, "*Purines*" (Wiley-Interscience, 1971), at p. 220), beginning with 4,5-diaminopyrimidines; to wit: (1) for the purines in general, *see* Brown, "*The Chemistry of Heterocyclic Compounds: Fused Pyrimidines*", Part II, The Purines, 1971), at pp. 31-90; (2) for the 9-dieazapurines in
- 10 particular, *see* Fox, *et al.*, *J. Org. Chem.*, 43:2536, 1978; (3) for the pteridines, *see*, for a description of the standard Timmis reaction, Nishigaki, *et al.*, *Heterocycles*, 15:757-759, 1981; Timmis, *Nature*, 164:139, 1949, (or other standard Traube-like protocols for preparing pteridines by ring closure of diamino-pyrimidines using a two carbon reagent); and, (4) for the pyrimidines, *see*, Schrage and Hitchings, *J. Org. Chem.*, 16:207, 1951.
- 15 Compounds of the invention, intermediates and compounds tested for comparison of activity to the compounds of the invention are identified in the discussion below by the numbers assigned to each compound in Table 1.

Table I. Physicochemical Data for all New Compounds and TNF- α Inhibition Data.

Compd Type	R ₁	R ₂	R ₃	X	Y	mp(°C)	formula	analyses ^a	TNFiAlC ₅₀ ^b
1	I	5-oxohexyl	Me	Me	H	102-103			85
2	I	(CH ₂) ₃ COOH	Me	Me	H	208-210			>200
4	I	CH ₂ COOEt	Me	Me	H	162-165	C ₁₁ H ₁₄ N ₄ O ₄	C ₂ H ₅ N	200
5	I	(CH ₂) ₃ COOEt	Me	Me	H	76-78	C ₁₂ H ₁₆ N ₄ O ₄	HRMS	10
6	I	(CH ₂) ₃ COOEt	Me	Me	H	73-75	C ₁₃ H ₁₈ N ₄ O ₄	C ₂ H ₅ N	6
7	I	(CH ₂) ₃ COOEt	Me	Me	H	84-85	C ₁₄ H ₂₀ N ₄ O ₄	C ₂ H ₅ N	11
8	I	CH ₂ PhCOOMe	Me	Me	H	158-160	C ₁₆ H ₁₆ N ₄ O ₄	C ₂ H ₅ N	>200
10	I	(CH ₂) ₃ COOEt	Me	Me	Br	101-102	C ₁₃ H ₁₇ BrN ₄ O ₄	C ₂ H ₅ N	60
11	I	CH ₂ PhCOOMe	Me	Me	Br	218-219	C ₁₆ H ₁₅ BrN ₄ O ₄	C ₂ H ₅ N	>200
12	I	(CH ₂) ₃ COOEt	Me	Me	SH	202-206	C ₁₃ H ₁₈ N ₄ O ₄ S	C ₂ H ₅ N	100
13	I	CH ₂ PhCOOEt	Me	Me	SH	>293 dec	C ₁₇ H ₁₈ N ₄ O ₄ S	C ₂ H ₅ N	>200
20	V	Me	n-heptyl	NO		>218 dec	C ₁₂ H ₂₀ N ₄ O ₃	C ₂ H ₅ N	ND ^c
24	I	n-hexyl	Me	H	OH	>295 dec	C ₁₂ H ₁₈ N ₄ O ₃	C ₂ H ₅ N	50
25	I	H	Me	H	SH	>320			>200
31	I	(CH ₂) ₃ COOEt	n-propylMe	II		oil	C ₁₅ H ₂₂ N ₄ O ₄	C ₂ H ₅ N	5

Compd	Type	R1	R3	R7	X	Y	mp(°C)	formula	analyses*	TNfatCS0*
33	V	Me	II		NH ₂		>270 dec	C ₁₁ H ₁₆ N ₄ O ₂	C ₁₁ H ₁₆ N	ND
34	II	Me	II		II	II	287-289	C ₁₁ H ₁₆ N ₄ O ₂	C ₁₁ H ₁₆ N	ND
35	II	n-propyl	H		II	H	187-189	C ₁₁ H ₁₆ N ₄ O ₄	C ₁₁ H ₁₆ N	ND
36	II	Me	(CH ₂) ₃ COOEt		II	II	90-92	C ₁₁ H ₁₆ N ₄ O ₄	C ₁₁ H ₁₆ N	12
36a	II	Me	(CH ₂) ₃ COOH		H	H	199-202	C ₁₁ H ₁₂ N ₄ O ₄	C ₁₁ H ₁₆ N	>200
37	II	n-propyl	(CH ₂) ₃ COOEt		H	H	53-55	C ₁₁ H ₂₀ N ₄ O ₄	C ₁₁ H ₁₆ N	5
37a	II	n-propyl	(CH ₂) ₃ COOH		H	H	97-99	C ₁₁ H ₁₆ N ₄ O ₄	C ₁₁ H ₁₆ N	>200
38	II	Me	CH ₂ CH=CHCOOMe		H	H	118-119	C ₁₁ H ₁₂ N ₄ O ₄	HRMS	25
39	II	Me	n-hexyl		COOMe	COOMe	92-95	C ₁₁ H ₂₂ N ₄ O ₆	C ₁₁ H ₁₆ N	ND
40	II	Me	II	Et	Et	Et	218-222	C ₁₁ H ₁₄ N ₄ O ₂	C ₁₁ H ₁₆ N	ND
41	II	Me	(CH ₂) ₃ COOEt		Et	Et	66-68	C ₁₁ H ₂₂ N ₄ O ₄	C ₁₁ H ₁₆ N	130
41a	II	Me	(CH ₂) ₃ COOH		Et	Et	161-162	C ₁₁ H ₂₀ N ₄ O ₄	C ₁₁ H ₁₆ N	ND
42	II	Me	II	Phenyl	II		>307 dec	C ₁₁ H ₁₀ N ₄ O ₂	C ₁₁ H ₁₆ N*	ND
43a	II	n-butyl	(CH ₂) ₃ COOEt		H	H	N/A	N/A	N/A	N/A
43b	II	n-pentyl	same		II	II	N/A	N/A	N/A	N/A
43c	II	isobutyl	same		II	II	N/A	N/A	N/A	N/A


Compd Type	R1	R3	R7	X	Y	mp(°C)	formula	analyses ^a	TNF α IC50 ^b
43d	II	tetrahydro-	same	II	H	N/A	N/A	N/A	N/A
43e	II	benzyl	same	II	II	N/A	N/A	N/A	N/A
		furfuryl							
43	II	Me	(CH ₃) ₂ COOEt	Phenyl	II	99-100	C ₁₉ H ₁₆ N ₂ O ₄	HRMS	>200
44	III	Me	n-heptyl			73-75	C ₂₂ H ₁₈ N ₂ O ₅ S	HRMS	75
45	III	Me	II			210-213	C ₂₁ H ₁₆ N ₂ O ₅ S	C ₂₁ H ₁₆ N	ND
46	III	n-propyl	H			142-144	C ₉ H ₈ N ₂ O ₅ S	C ₉ H ₈ N	ND
47	III	Me	(CH ₃) ₂ COOEt			45-47	C ₁₁ H ₁₄ N ₂ O ₅ S	C ₁₁ H ₁₄ N	25
47a	III	Me	(CH ₃) ₂ COOH			121-122	C ₉ H ₁₀ N ₂ O ₅ S	HRMS	>200
48	III	n-propyl	(CH ₃) ₂ COOEt			oil	C ₁₁ H ₁₆ N ₂ O ₅	C ₁₁ H ₁₆ N	18
51	IV	Me	(CH ₃) ₂ COOEt			oil	C ₁₄ H ₁₆ N ₂ O ₅	C ₁₄ H ₁₆ N ^c	ND
52	IV	Me	(CH ₃) ₂ COOEt			oil	C ₁₃ H ₁₄ N ₂ O ₄	C ₁₃ H ₁₄ N ^b	55
52a	IV	Me	(CH ₃) ₂ COOH			163-165	C ₁₀ H ₁₄ N ₂ O ₄	C ₁₁ H ₁₆ N	>200

^a All compounds analyzed for C, H, N or by exact mass high resolution mass spectrometry; results were within $\pm 0.4\%$ of theoretical values.
^b Concentration of compound in μM which inhibited the production of TNF α by 50% of control. ND = not determined. C: calc'd, 58.61; found, 59.22. H: calc'd, 4.13; found, 3.70. N: calc'd, 10.25; found 9.77. C: calc'd, 59.62; found, 60.61. Compound types are: I=purines; II=pteridines; III=thiadiazolopyrimidines; IV=quinazolines; and, V=isoquinolones. "N/A" means data not available (but can be obtained through conventional analysis techniques).

-12-

B. Purine synthesis.

The purines of the invention have the general formula (I):



wherein Z is N or CH;

R_1 is $(CH_2)_nA$, where:

- 5 A is NH_2 , acyloxy, SO_3H , PO_4H_2 , $NNO(OH)$, SO_2NH_2 , $PO(OH)NH_2$, SO_2R or $COOR$ where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

- n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of
 10 a carbon atom to form, respectively, ether or amino linkages;
 and, preferably, R_1 is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above);

- R_2 is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl,
 15 aralkyl having 1 to 7 carbon atoms or a ω -hydroxyalkyl having from 1 to 7 carbon atoms;

R_3 is the same as R_2 , and,


X is H, any halogen, OH, SH, OR' , or SR' , where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 4 carbon atoms.

- 20 These compounds are synthesized per the below synthesis scheme (which is described in further detail in the Examples).

SCHEME 1


(PURINES)

Three basic synthesis protocols were utilized in Scheme 1; to wit:

Method A

- 5 Generally, theobromine was used as the starting material under conditions to ensure N-1 alkylation took place in lieu of O-6 alkylation. Compounds 4 through 8, 10 and 11 (Table I) were prepared by this method. Compounds 10 and 11 in particular were prepared by a variation of the alkylation method in which theobromine was first brominated to give 8-bromotheobromine (compound 9), then alkylated. The 8-bromo
- 10 substituent was also displaced by NaSH to yield the corresponding 8-thio derivatives, compounds 12 and 13.

-14-

Method B


This method is essentially based on the Traube purine synthesis protocol referred to *supra*. The method was used to prepare 1,3,8-trisubstituted xanthines bearing no alkyl group at the N-7 position. In this procedure, the N-1 substituted pyrimidine was

5 alkylated at position N-3. Formation of the purine ring was complete by nitrosation, reduction of the nitroso to the amine by catalytic hydrogenation, then ring closure using urea or potassium ethyl xanthate to provide compounds 24 and 25 (respectively,

-15-

8-oxo and 8-thioxo derivatives). A detailed description of this protocol is provided in the Examples.

Method C



- (a) diethylcyanomethyl acetate
(b) CH₂Br, NaOH
(c) 3,5-dimethyl-4-pyridyl, K₂CO₃


This method was utilized to prepare the N-3 propylpurines. The starting material used
5 was n-propyl urea condensed with ethyl cyanoacetate in the presence of sodium
ethoxide to yield the 6-amino-1-propylpyrimidinedione in moderate yield.
Commercially available 3-n-propylxanthine could also be used as the starting material.

-16-

Ring closure was accomplished as described in method A, except that diethoxymethyl acetate was used as the source of carbon in the ring closure step. Sequential alkylations were then performed using alkyl halides to yield the final compound 31 (ethyl 4-(2,3,6,7-tetrahydro-2,6-dioxo-7-methyl-3-n-propyl-1H-purin-1-yl)butanoic acid). A detailed description of this protocol is provided in the Examples.

C. Pteridines synthesis.

The pteridines of the invention have the general formula (II):



R_1 is $(CH_2)_nA$, where:

A is NH_2 , acyloxy, SO_3H , PO_4H_2 , $NNO(OH)$, SO_2NH_2 , $PO(OH)NH_2$, SO_2R or $COOR$ where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages;

and, preferably, R_1 is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above);

-17-

R_2 is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a ω -hydroxyalkyl having from 1 to 7 carbon atoms;

R_4 is the same as R_2 , OH or an O-alkyl having from 1 to 5 carbon atoms;

5 R_5 is the same as R_2 , OH or an O-alkyl having from 1 to 5 carbon atoms; and,

Z is N or CH.

These compounds are synthesized per the below synthesis scheme (which is described in further detail in the Examples).



SCHEME II

10

(PTERIDINES)


Method C (above) was chosen as a convenient method to produce N-alkyls in preference to O-alkyls in this group. Method C was modified to this end as follows:

-18-



$\text{II, } \text{C}_4\text{H}_9$ COOMe COOMe
 $\text{IV, } \text{H}$ phenyl H
 $\text{VI, } (\text{CH}_2)_4\text{COOEt}$ phenyl H

- (a) $\text{Na}_2\text{S}_2\text{O}_8, \text{H}_2\text{O}$
 (b) 2,4-dichloroquinone
 (c) R_1X DMF, $\text{X} = \text{Cl}, \text{Br}$
 (d) pyrimidinone
 (e) purine
 (f) 6-aminopurine




$\text{II, } \text{Me}$ H
 $\text{IV, } \text{C}_4\text{H}_9$ H
 $\text{VI, } \text{Me}$ $(\text{CH}_2)_4\text{COOEt}$
 $\text{40, } \text{Me}$ $(\text{CH}_2)_4\text{COOH}$
 $\text{41, } \text{C}_4\text{H}_9$ $(\text{CH}_2)_4\text{COOEt}$
 $\text{41a, } \text{Me}$ $\text{CH}_2\text{CH}=\text{CHCOOMe}$

-19-

Synthesis of the pteridines was based on orthodiaminopyrimidines as precursors. Ring closure of the orthodiamines (compounds 33 and 28) was accomplished with a two carbon source (e.g., glyoxal) to produce compounds 34 and 35 (N-1 substituted pteridines). Alkylation at N-3 as described with respect to Method A produced the
 5 desired pteridines (compounds 36-38). Further, use of 3,4-hexanedione in the ring closure step produced a more lipophilic derivative (compound 41; 6,7-diethyl pteridine). Condensation of compound 22 with dimethylacetylene dicarboxylate formed compound 39 (1,3-dialkylpteridine), while treatment of compound 27 with phenethyl amine followed by alkylation provided compound 43 (6-phenyl dialkyl
 10 pteridine). Both of the latter protocols utilized a Timmis reaction to produce the desired products. A detailed description of these protocols is provided in the Examples.

D. Thiadiazolo-Pyrimidine synthesis.

The thiadiazolo pyrimidines of the invention have the general formula (III):



R_1 is $(CH_2)_nA$, where:

- 15 A is NH_2 , acyloxy, SO_3H , PO_4H_2 , $NNO(OH)$, SO_2NH_2 , $PO(OH)NH_2$, SO_2R or $COOR$ where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of
 20 a carbon atom to form, respectively, ether or amino linkages;

-20-

and, preferably, R_1 is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above); and

R_2 is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a ω -hydroxyalkyl having from 1 to 7 carbon atoms.


These compounds are synthesized per the below synthesis scheme (as described in further detail in the Examples).

SCHEME III

10

(THIADIAZOLOPYRIMIDINES)

Method C (above) was chosen as a convenient method to produce N-alkyls in preference to O-alkyls in this group. Method C was modified to this end as follows:




-21-

Synthesis of the pyrimidines was based on orthodiaminopyrimidines as precursors. Ring closure of the orthodiamines was accomplished by treatment with thionyl chloride in the presence of pyridine. Alkylation of these intermediates produced compounds 47 and 48 (disubstituted pyrimidines). A detailed description of this protocol is
 5 provided in the Examples.

E. Isoquinoline Synthesis.

The isoquinolines of the inventions have the general formula (IV):



R₂ is (CH₂)_nA, where:

A is H, NH₂, acyloxy, SO₃H, PO₄H₂, NNO(OH), SO₂NH₂, PO(OH)NH₂, SO₂R or
 10 COOR where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages;

15 and, preferably, R₂ is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above); and

R₃ is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms) or a ω -hydroxyalkyl having from 1 to 4 carbon atoms;

20

R₄ is H, OH, NH₂ or O-alkyl having from 1-7 carbon atoms;

-22-

R_6 is H, OH, NO, NO_2 , NH_2 , an O-alkyl having from 1-4 carbon atoms, or X where:

where X is H, any halogen, OH, SH, OR' , or SR' , where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 4 carbon atoms; and,

R_7 is H, OH, NO, NO_2 , NH_2 , an O-alkyl having from 1-7 carbon atoms, or X where:

5 where X is H, any halogen, OH, SH, OR' , or SR' , where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 7 carbon atoms.

These compounds were synthesized by purchasing isoquinolines from Aldrich Chemical (see, FIGURE 14) and adding side chains to the ring structure as described above and in the Examples with respect to the purine, pteridine and thiadiazolopyrimidine
10 compounds of the invention. Only the 6,7-dimethoxy-1(2H)-isoquinoline compound (Aldrich # S52,626-6) had any inhibitory effect on $\text{TNF-}\alpha$ production prior to addition of the side chains described above (see, Example 7).


F. Quinazoline Synthesis.

The quinazolines of the invention are synthesized according to the following scheme
15 and are represented in structure by Compound 52:

SCHEME IV

(DIDEAZAPTERIDINES OR QUINAZOLINES)

Compound 52 (a quinazoline derivative; ethyl 4-(1-methyl-2,4-dioxoquinazol-3-yl)butanoic acid) was produced as follows:
20



-23-

The starting material for this protocol was N-methyl isatoic anhydride. A detailed description of this protocol is provided in the examples.

II. Methods for Use of the Inventive Compounds.

- The compounds of Formulas I through IV may be administered to a mammalian host
- 5 to retard cellular responses associated with TNF- α and IL-1 production and activation of the ceramide-mediated signal transduction pathway. In particular, the compounds of the invention may be administered to a mammal to retard activation of ceramide-dependent intracellular biochemical pathways in target cells without inhibiting the activity of phosphodiesterase in the target cells or affecting the levels of diacylglycerol
- 10 therein. As exemplified herein, the methods of the invention are expected to be of particular use in providing protection against inflammation and excessive formation of fibrotic tissue by reducing the production of TNF- α by stimulated monocytes. As further exemplified herein, the compounds of the invention (particularly the isoquinolines and pteridines) are also expected to be efficacious in providing protection
- 15 against cell senescence or cell apoptosis, such as occurs as a result of trauma (e.g., radiation dermatitis) and aging (e.g., of the skin and other organs). In this context, the phrase "providing protection against" means clinically significant inhibition of cellular responses to stimuli (signals) whose transmission to the cell is facilitated in whole or in part by the ceramide-mediated, sphingomyelin signal transduction pathway.
- 20 For purposes of this disclosure, therefore, inflammation, fibroblast proliferation, cell senescence and cell apoptosis in response to ceramide-mediated signal transduction through the sphingomyelin pathway will be considered to be "ceramide associated" conditions. Those of ordinary skill in the art will be familiar with, or can readily ascertain, the identity and clinical signs of specific ceramide associated conditions, and
- 25 can identify clinical signs of improvement therein (such as reductions in serum levels of TNF- α and improvement in clinical health) in addition to those exemplified herein.

-24-

For administration, the compounds of the invention will preferably be formulated in a pharmaceutically acceptable carrier. Such carriers include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable
5 organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.

Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and
10 nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.

Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, microcrystalline cellulose, polymer hydrogels
15 and the like. Similarly, the carrier or diluent may include any time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, microcapsules, microspheres, liposomes, and hydrogels. For further reference, those of skill in the art may wish to consult the standard reference *Remington's Pharmaceutical Sciences* (which is incorporated herein by reference to
20 illustrate knowledge in the art concerning suitable pharmaceutical carriers).

A wide variety of pharmaceutical forms can be employed. Thus, when using a solid carrier the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche, lozenge or suppository. When using a liquid
25 aqueous or nonaqueous liquid suspension. Topical administration via timed release skin patches is also a suitable pharmaceutical form.

-25-

Dosages of the compounds of the invention will vary depending on the age, weight and presenting condition of the host to be treated, as well as the potency of the particular compound administered. Such variables will readily be accounted for by those of ordinary skill in the clinical art. In particular, dosages will be adjusted upward or
5 downward for each recipient based on the severity of the condition to be treated and accessibility of the target cells to the pharmaceutical formulations of the invention. Where possible, it will be preferable to administer the pharmaceutical formulations of the invention locally at the site of the target cells; e.g., onto inflamed skin or by infusion to another organ of the host. Thus, dosages will also vary depending on the
10 route of administration and the extent to which the formulations of the invention are expected to reach target cells before dilution or clearance of the formulation. Preferred routes of administration are by topical administration, local injection or parenteral infusion, although oral and intravascular routes may also be utilized.

Generally, based on experience with other inhibitors of intracellular responses to
15 external stimuli (such as pentoxifylline) and the data provided herein, good results can be expected to be achieved in an adult host of about 60 kg. body weight in a dosage range of about 500 to about 4,000 mg/day, preferably between about 1,000 and about 3,500 mg/day (i.e., a "therapeutically effective dosage"). These dosages may be combined with other conventional pharmaceutical therapies for inflammation and
20 fibrosis; e.g., administration of non-steroidal anti-inflammatory medications.

The compounds of the invention vary in potency. A summary of the potency of each compound (expressed as a percentage of inhibition of intracellular responses to LPS, namely, the production of $\text{TNF-}\alpha$, where responses to pure LPS=100% and are measured as the concentration of the inventive compound needed to inhibit $\text{TNF-}\alpha$
25 production by 50%) is provided in Table 1, above. Those of ordinary skill in the art will recognize that lesser or greater dosages of the compounds of the invention may be required depending on the potency of the particular compound being administered.

III. Methods For Identification Of Therapeutically Effective Analogues Of The Compounds Of The Invention.

Those of ordinary skill in the art will be familiar with means to develop analogues to the compounds specifically described herein which, although not structurally identical thereto, possess the same biological activity. Such compounds are within the scope of the invention and may be identified according to the protocols described below and in the Examples.

Through exposure of cells to the compounds of the invention under controlled conditions, the responsiveness of cells to inflammatory agents and intracellular mechanisms therefor can be investigated. This information will not only better elucidate the intracellular pathways responsible for cellular responses to particular stimuli, but will also aid in the identification of anti-inflammatory and anti-fibrosis therapeutic compounds.

To identify and select therapeutic compounds for use in treating ceramide-associated conditions such as inflammation and fibrosis, cells (or intracellular components such as microsomes) which have not been exposed to an inflammatory or fibroblast proliferation inducing agent (e.g., LPS, TNF- α , IL-1, PDGF) are exposed to such an agent and the candidate therapeutic compound. Specifically, a control group of cells is incubated with a known amount of the inflammatory or fibroblast proliferation inducing agent. Treatment groups of cells are exposed to the same amount of inflammatory or fibroblast proliferation inducing agent as well as aliquots of the candidate therapeutic compound. Inflammatory responses or fibroblast proliferation in each group are detected by conventional means known to those of skill in the art (such as the assay steps described in the examples) and compared.

To identify and select therapeutic compounds for use in treating ceramide-associated conditions of cell senescence and apoptosis, cells (or intracellular components such as microsomes) which have not been exposed to a senescence or apoptosis inducing agent

-27-

(e.g., cytokines such as TNF- α and exogenous stimuli such as heat, radiation and chemical agents), are exposed to such an agent and to the candidate therapeutic compound. Inhibition of senescence or apoptosis is measured as a function of cell growth. Those of ordinary skill in the art will be familiar with techniques for
5 obtaining such measurements, examples of which are provided below.

"Therapeutically effective compounds" will be those which, when administered according to the invention and sound medical practices, provide cells with protection against ceramide-associated conditions compared to control values for cellular reactions to a ceramide-associated condition inducing agent.

10 The invention having been fully described, examples illustrating its practice are set forth below. These examples should not, however, be considered to limit the scope of the invention, which is defined by the appended claims.

In the examples, the abbreviation "min." refers to minutes, "hrs" and "h" refer to hours, and measurement units (such as "ml") are referred to by standard abbreviations. "mp"
15 refers to melting point.

-28-

EXAMPLE 1
INHIBITION OF CELL SENESCENCE AFTER SERUM DEPRIVATION
IN SERUM-DEPENDENT CELLS

Many cell types are dependent upon serum factors for growth. Thus, deprivation of
5 such cells of serum provides a model for assessment of compounds to modulate cell
responses to intracellular ceramide-mediated signal transduction. In particular,
withdrawal of serum from serum-dependent cell cultures produces increased
intracellular levels of endogenous ceramide and may also increase intracellular levels
of endogenous diacyl glycerol (see, e.g., Jayadev, *et al.*, *J.Biol.Chem.*, 270:2047-2052,
10 1995).

To evaluate the inhibitory effect of the compounds of the invention on ceramide-
associated conditions *in vitro*, the serum withdrawal model was used. Specifically, 3T3
fibroblast cells were seeded in 96 well microtiter plates in DMEM in the presence of
10% fetal bovine serum. The cells were incubated to 90% confluence.

15 The medium was removed, the cells washed and reincubated in serum-free DMEM.
Compound no. 37 and cell permeable ceramide were added to the wells at
concentrations of, respectively, 0, 4, 40 or 400 μ m compound no. 37 and 0, 5 or 10
 μ m of ceramide. After 24 hrs. incubation, 0.5 μ Ci of [3 H] thymidine was added to
each well for 2 hrs. DNA synthesis in the tested cell population was assessed by
20 conventional techniques for detection of [3 H] thymidine incorporation. The results of
this assay are indicated in FIGURE 1 and establish the cell senescence inhibitory
efficacy of the inventive compounds (as represented by compound no. 37).

EXAMPLE 2
INHIBITION OF CELL APOPTOSIS AFTER CD95 STIMULATION

25 Engagement of cell surface receptor CD95 (also known as Fas/Apo-1 antigen) triggers
cell apoptosis. DX2 is a functional anti-FAS (CD95) antibody which will, on binding
of CD95, activate the Smase catalysis of sphingomyelin hydrolysis and production of
ceramide (see, re DX2, Cifone, *et al.*, *J.Exp.Med.*, 177:1547-1552, 1993, the disclosure
of which is incorporated herein by reference for use in accessing the DX2 antibody).

Thus, binding of CD95 is a model for induction of apoptosis via the sphingomyelin signal transduction pathway.

To assess the inhibitory effect of the compounds of the invention on ceramide-mediated cell apoptosis, human T lymphoblasts (Jurkat) were suspended at 2×10^6 cells per ml. in RPMI-1640 supplemented with insulin, transferrin, selenium and glutamine. After incubation for 2 hrs. at room temperature with either compound no. 37, compound no. 6, pentoxifylline or a control compound (Ro-1724), 25 ng/ml of anti-FAS antibody was added to each suspension. After another 2 hrs., cell apoptosis was measured as a function of the number of cells (counted by hemocytometer) that excluded the vital dye erythrosin B. The results of the experiment are indicated in FIGURE 2 and establish the apoptosis inhibitory efficacy of the compounds of the invention (as represented by compounds nos. 6 and 37, particularly the latter).

To assess the inhibitory effect of the compounds of the invention on death of human lymphocytes, human peripheral blood lymphocytes were isolated from normal human blood and depleted of monocytes by adherence to a plastic substrate. Lymphocytes were then cultured in RPMI-1640 medium with 10% autologous plasma at an initial concentration of 2×10^6 cells per ml. Aliquots of the cell samples were divided and one half of the samples were incubated with either compound 37 or compound 1L-49 (an isoquinolone, the structure of which is shown in Example 7) for four days. The remaining half of the samples were allowed to rest for four days. Cell viability after four days was determined by erythrosin B dye exclusion in a hemocytometer.

As shown in FIGURE 13, at increasing concentrations, the compounds of the invention (as represented by compounds 37 and 1L-49) protected the cell sample population from death by up to 100% as compared to the survival rate of untreated lymphocytes.

EXAMPLE 3
INHIBITION OF THE ACTIVITY OF CERAMIDE ACTIVATED PROTEIN
KINASE

Ceramide-activated protein kinase (CaPK) is a 97 kDa protein which is exclusively
5 membrane-bound and is believed to serve a role in the sphingomyelin signal
transduction pathway. In particular, CaPK is believed to mediate phosphorylation of
a peptide derived from the amino acid sequence surrounding Thr⁶⁶⁹ of the epidermal
growth factor receptor (i.e., amino acids 663-681). This site is also recognized by the
mitogen-activated kinase MAP (also known as a family of extracellular signal-regulated
10 kinases). Thus, the effect of the compounds of the invention on CaPK activity in cells
is indicative of the effect that the compounds exert on signal transduction in the
sphingomyelin pathway.

To that end, Jurkat cells were suspended at 2×10^6 cells per ml in RPMI-1640 medium
as described in Example 2. After incubation for 2 hrs., either compound 37, 20 μ m of
15 ceramide or 25 ng/ml of anti-FAS antibody DX2 were added to each suspension and
incubated for 15 mins. After centrifugation and washing, the cells were separately
homogenized in a dounce homogenizer.

Ceramide kinase levels in each test sample were assayed as described by Liu, *et al.*,
J. Biol. Chem., 269:3047-3052, 1994 (the disclosure of which is incorporated herein for
20 reference and use in assaying ceramide kinase). Briefly, the membrane fraction was
isolated from each test sample of treated cell homogenate by ultracentrifugation and
run on a 10% PAGE gel. The gel was washed with guanadine-HCL, and renatured in
HEPES buffer. Then [³²P]-ATP was added to the gel and left there for 10 mins.
Thereafter, the gel was extensively washed with 5% TCA. Autophosphorylated kinase
25 was detected by autoradiography. The results of this assay are indicated in FIGURE
3, and establish the CaPK inhibitory efficacy of the compounds of the invention (as
represented by compound 37).

-31-

EXAMPLE 4
ABSORBANCE OF UVB RADIATION BY THE COMPOUNDS OF THE INVENTION

Radiation (particularly in the UVB wavelength) is a major cause of skin damage (including apoptosis) in humans. As indicated elsewhere above, the sphingomyelin signal transduction pathway is believed to be involved in at least the early stages of development of radiation induced dermatoses (including radiation dermatitis, sunburn and UVB induced immune suppression from radiation damage to Langerhans cells in the skin; see, e.g., Haimovitz-Friedman, *et al.*, *J.Exp.Med.*, 180:525-535, 1994 [cellular responses to ionizing radiation]; and, Kurimoto and Streilein, *J.Immunol.*, 145:3072-3078, 1992 [cutaneous immune suppression from UVB exposure]). Thus, a compound which will inhibit cell responses to stimulus of the sphingomyelin signal transduction pathway by radiation and can be administered topically at the site of exposure would be of great benefit in retarding the damage associated with radiation exposure (e.g., through exposure to sunlight or radiation).

To assess the radiation absorbing abilities of the compounds of the invention, the ultraviolet spectra of compounds of the invention (nos. 6 and 37, alone, in combination and as 8-oxo derivatives) were evaluated and compared to those of a commercially available sunscreen additive (PABA) and isoquinoline. The spectra were identified using a KONTRON analytical instrument. As indicated in FIGURE 4, the compounds of the invention (as represented by compounds nos. 6 and 37) absorbed through most of the UVB region, indicating efficacy in absorbing radiation. Surprisingly, a mixture of compound nos. 6 and 37 proved to absorb throughout the UVB region. Thus, given the somewhat greater absorbance characteristics of compound 37 vis-a-vis compound 6, it can be reasonably expected that mixtures of the two in ratios of 1:1 or greater (favoring compound 37) will have substantial synergistic efficacy in absorbing radiation and retarding its effects on cells.

-32-

EXAMPLE 5
INHIBITION OF TNF- α PRODUCTION
BY THE COMPOUNDS OF THE INVENTION

As shown in FIGURE 5(a), compounds of the invention having N-1 chain lengths from
5 2-5 carbons are especially useful in inhibiting TNF- α production *in vitro*, while N-1
chain lengths of about 4 carbons (with a terminal ester) appear to be optimal in this
respect (as compared to a control compound; FIGURE 5(b)). Further, the esterified
compounds were significantly more effective inhibitors of TNF- α production than their
carboxylic counterparts. These data were obtained as follows:

10 Peripheral blood mononuclear cells were isolated from normal human blood on
Hypaque-Ficoll density gradients. A portion of the isolated cells were further purified
by adherence to gelatin coated flasks.

100 μ l aliquots of monocytes were placed onto 96 well microtiter plates at a density of
5x10⁵ cells/ml in RPMI 1640 medium containing 10% fetal bovine serum. After
15 incubation for 24 hrs, various concentrations of the test compounds (FIGURE 5) were
added to the plated cells in a volume of 100 μ l and incubated for 1 hr. After
incubation, 1 μ g/ml of LPS was added to each well.

18 hrs after exposure of the plated cells to LPS, 100 μ l of medium was collected from
each well and assayed (by ELISA) for release of TNF- α , using recombinant human
20 TNF as a standard. The sensitivity of the assay ranged from 10-100pg/ml.

EXAMPLE 6
RELATIVELY LOW INHIBITION OF PHOSPHODIESTERASE IV
ACTIVITY BY COMPOUNDS OF THE INVENTION

As shown in FIGURE 6, there appears to be little correlation between the efficacy of
25 the compounds of the invention in inhibiting the activity of phosphodiesterase and
inhibiting activity of TNF- α . For example, the most active pteridine compound in
inhibiting TNF- α production *in vitro* (#37) was a very poor inhibitor of
phosphodiesterase IV, even at micromolar concentrations.

-33-

These data confirm that the compounds of the invention do not target phosphodiesterase to control TNF- α production. The data were obtained as follows:

The reaction was started with the addition of PDE and incubated at 37°C for 10 minutes, then terminated by boiling for 2 minutes. 500 μ l of 0.1 M HEPES/0.1 M NaCl (pH 8.5) was added to each tube, then the reaction mixture was applied to a boronate column. Unreacted cAMP was washed off with Hepes/NaCl and the reaction mixture eluted with acetic acid. Recovery was determined with the [14 C]-AMP.

EXAMPLE 7

IN VIVO AND IN VITRO LEUKOPENIA IN RESPONSE TO LPS AND INHIBITION OF SAME BY THE COMPOUNDS OF THE INVENTION

As shown in FIGURES 7 through 9 and Table I, the compounds of the invention effectively reduce cellular response to LPS, a known inducer of TNF- α production. In the presence of ceramide, the inhibitory activity of the compounds of the invention on LPS induced leukopenia (a phenomenon dependent on TNF- α induced surface expression of the P-selection class of adhesion molecules) was enhanced (FIGURE 7). However, the inhibitory activity of the compounds of the invention was essentially unaffected by diacylglycerol (FIGURE 8), indicating that the mode of action of the compounds of the invention are not dependent on hydrolysis of phosphatidic acid. These data were obtained as follows:

The leukopenia inhibitory capacity of the test compounds was determined by intraperitoneal administration of 0.5 μ g of LPS in saline to ICR female mice (age 6-8 weeks; weight 19-23 g). One hour before receiving the LPS, the mice received the test compound by intraperitoneal injection at a dose of 50 mg/kg (in isotonic saline). Two hours after injection of LPS, 200 μ l of blood was collected from each mouse into a heparinized tube and the total count of nucleated cells determined in a hemocytometer (FIGURES 7 and 9).

Calcium independent protein kinase activity was measured, using a 1% triton X-100 extract of Jurkat cells (5×10^8 /ml). The reaction mixture consisted of 20 mM Tris HCl

-34-

pH 7.5, 20 mM MgCl₂, 20 uM ATP containing 200,000 cpm [γ 32P] ATP, and 50 uM Myelin Basic Protein. The extract was pre-incubated with A) compound 37 B) compound 37 with or without 10 uM ceramide C) ceramide or D) dihydro ceramide for 15 minutes, followed by addition of substrate and ATP, and incubation at 30°C for 5 minutes. The total count of nucleated cells was measured in a hemocytometer (FIGURE 9). The same protocol was followed to obtain the results shown in FIGURE 8 (with the addition of diacyl glycerol to some of the test mixtures).

A isoquinoline compound of the invention was also tested *in vitro* for its inhibitory efficacy with respect to LPS induced TNF- α production in human cells. The structure of the compound, 11-49, is described below:

-35-

- Human macrophages were cultured in 96 well microtiter plates and incubated with LPS. Aliquots of the stimulated cells were then incubated with, respectively, 0.1, 1, 10, 100 or 1000 μ m of 11-49, compound 37 and a commercially available isoquinoline (6,7-dimethoxy-1(2H)-isoquinoline from Aldrich Chemical; labelled S52-626-6 in
- 5 FIGURE 10) which, like the compounds of the invention, has an oxygen *ortho* to a ring nitrogen but, *unlike* the compounds of the invention, lacks a side chain substituent as described above (11-49 is representative of the isoquinolone compounds of the invention having the side chain substituents described elsewhere above). The inhibitory efficacy of each compound was measured as a function of TNF- α reduction in pg/ml.
- 10 The results of the experiment are indicated in FIGURE 10 and establish that the compounds of the invention (represented by 11-49 and compound 37) have inhibitory efficacy with respect to reduction in LPS induced TNF- α production by human cells. Other isoquinolines tested (FIGURE 14) did not exert inhibitory activity in the absence of the side chain substituents added according to the invention.

15

EXAMPLE 8
FIBROBLAST PROLIFERATION IN RESPONSE TO LPS
AND INHIBITION OF SAME
BY THE COMPOUNDS OF THE INVENTION

- As shown in FIGURE 11, PDGF induced fibroblast proliferation was selectively
- 20 inhibited by the compounds of the invention. In addition, the compounds were shown not to be cytostatic or cytotoxic, insofar as they did not alter EGF-triggered mitogenesis in the cells tested (FIGURE 12). These data were obtained as follows:

- Mouse fibroblast line 3T3 cells (American Type Culture Collection #CCL 92) were seeded into 96 well plates in complete medium and allowed to grow to confluence.
- 25 The medium was then replaced with medium-free serum and the cells incubated for 24 hrs.

The test compounds were then incubated with the cells for 1 hr before addition of 5ng/ml human PDGF or EGF was added to each well. After another 24 hrs, 1 μ Ci of [³H]-thymidine was added to each well. 4 hrs later the cells were harvested onto glass fiber filters and the cellular incorporation of [³H]-thymidine was measured by liquid
5 scintillation counting (FIGURES 11 and 12).

EXAMPLE 9

SYNTHESIS OF COMPOUNDS 2, 4-8 AND 10-13

General Alkylation Procedure for Compounds 4-8, 10,11 (Method A):

Theobromine or 8-bromotheobromine (2 mmol) was combined with anhydrous K₂CO₃ (2.5 mmol) and dry DMF (15 mL) and the mixture was brought to 75°C. The
10 appropriate alkyl halide (2.5 mmol) was added and the mixture was stirred at 75°C for 2-18 h. The reaction mixture was cooled, poured into water (125 mL) and extracted with ethyl acetate (2 x 75 mL). The organic layer was dried over magnesium sulfate and evaporated to yield a colorless oil or white solid which was triturated with ethyl
15 ether. The resulting solid, often analytically pure, may be purified further if desired by crystallization from a small amount of ethanol. Yields 58-89%. Compounds 15-17, 31, 36-38, 41, 43, 47, and 48 (described below) were prepared by this same procedure only using the appropriate precursors in place of theobromine.

General Thiation Procedure for Compounds 12 and 13:

20 The 8-bromoxanthine 10 or 11 (0.25 mmol) was suspended in anhydrous ethanol (10 mL) and heated to reflux. NaSH.H₂O_x (2.5 mmol) was added and the mixture became clear, green almost immediately. The mixture was stirred under reflux for 30 min, cooled and evaporated onto silica gel. Flash column chromatography using 5-7% MeOH in CH₂Cl₂ provided a 63% and 75% yield of 12 and 13, respectively as white
25 solids. Note: Compound 13 was found by ¹H NMR to be the ethyl ester due to transesterification under the reaction conditions.

¹H NMR spectra and elemental analyses or exact mass data were consistent with the assigned structures (see, Table 2 following Example 13).

-37-

EXAMPLE 10

SYNTHESIS OF COMPOUNDS 24, 25, 31 AND INTERMEDIATES

General Procedure for C-Nitrosation of Pyrimidines (Compounds 18-20, 27, and 32):

The pyrimidine (15 mmol) was suspended in 1N HCl (30 mL) and an aqueous solution
5 of sodium nitrite (20 mmol in 10 mL) was dripped in with stirring over 10 min. The suspension went from off-white to purple almost immediately. Stirring was continued for 1h, pH adjusted to 5 with ammonia water and the purple solid product collected to provide 75-90% yield after drying. The characteristic lack of the C-5 proton in the ¹H NMR was evident for each compound (Table 2).

10 General Procedure for the Reduction of 5-Nitroso to 5-Amino Pyrimidines (Compounds 21-23, 28, and 33):

The 5-nitrosopyrimidine (15 mmol) was suspended in water (50 mL) and heated to 80-90°C. With stirring, sodium hydrosulfite (45 mmol) was added in portions over 5 min. The color quickly changed from purple to light green and stirring was continued an
15 additional 10 min. The mixture was cooled in ice and filtered. The filtered solid was washed with cold water, EtOH and Et₂O to provide the orthodiamine in 70-88% yield as a tan to pale green solid.

Synthesis of 1-n-Hexyl-3-methyluric acid intermediate (24):

The nitrosopyrimidine 19 (270 mg, 1.06 mmol) was dissolved in ethanol (20 mL) with
20 warming and palladium on carbon (75 mg, 10%) was added under argon. Hydrogenation was performed at room temperature and 15 psi for 2 h, filtered to remove catalyst and evaporated to dryness. The residue was combined with urea (600 mg, 10 mmol) and heated neat on the hot plate with stirring. The temperature reached 140°C which produced a clear melt and was maintained for about 10 min. with
25 additional urea added (1g). Upon cooling the melt solidified and was dissolved in 1N NaOH (25 mL) and boiled with decolorizing carbon for 10 min., filtered and acidified to pH 3-4 while hot. The resulting precipitate was collected after cooling and washed

-38-

with water and dried to yield 160 mg (57%) of **24** as an off-white solid with the following characteristics: mp >290°C dec. ¹H NMR (500 MHz, DMSO-d₆) δ 11.80 and 10.73 (2s, 2H, N-7 H, N-9 H), 3.78 (t, 2H, N-CH₂), 3.30 (s, 3H, N-CH₃, under H₂O signal), 1.48 (m, 2H, 2'CH₂), 1.24 (m, 6H, 3', 4', 5' CH₂), 0.85 (t, 3H, CH₃).

5 Analysis: C₁₂H₁₈N₄O₃ (C, H, N; Table 2).

Synthesis of 3-Methyl-8-thiouric acid (**25**) intermediate:

The pyrimidinediamine **33** (100 mg, 0.63 mmol) was combined with potassium ethyl xanthate (810 mg, 5 mmol) and DMF (10 mL) and heated at 100°C. The suspension became green almost immediately and reaction was complete after 30 min. by TLC.

10 After a total reaction time of 1 h, the mixture was cooled, filtered and washed with Et₂O, dried to yield an off-white solid (310 mg) which presumably contained the unreacted potassium ethyl xanthate and the potassium salt of the desired product. The solid was suspended in water (5 mL) and heated to dissolve. Glacial acetic acid was added to pH 5 and a vigorous effervescence was noted. A white solid formed which
15 was filtered warm and washed with water, then ethanol and dried to yield 99 mg (79%) of the title compound. ¹H NMR (DMSO-d₆) δ 13.40, 12.92 and 11.80 (3br s, 3H, NHs), 3.28 (s, 3H, CH₃). Analysis: C₆H₆N₄O₂S (C, H, N; Table 2).

Synthesis of 3-n-Propylxanthine (**29**) intermediate:

The pyrimidinediamine **28** (750 mg,) was combined with diethoxymethyl acetate (7
20 mL) and heated at 80° C for 2 h. The mixture was evaporated to dryness and water (5 mL) was added and the mixture heated for 20 min. to near boiling. The resulting solution was then allowed to evaporate slowly to yield off-white crystals. Yield 680 mg (86%); mp 282-284°C, Lit.¹⁵ 291-292°C.

EXAMPLE 11
SYNTHESIS OF COMPOUNDS 36-39, 41 AND 43 AND INTERMEDIATES

General Procedure for Ring Closure of Pyrimidine-diamines to Pteridines:

The orthodiamine **28** or **33** (2 mmol) was suspended in water (20 mL) and heated to
5 above 70°C before a solution of glyoxal-sodium bisulfite addition product (10 mmol
in 25 mL water) was added with stirring. The pale green suspension slowly became
light amber and clear. After heating 5 min TLC indicated reaction was complete. The
mixture was cooled and extracted with ethyl acetate (5 x 40 mL), dried over MgSO₄
and evaporated to yield the 1-methyl (**34**) or 1-n-propylpteridine (**35**) in 71 and 78 %,
10 respectively. ¹H NMR showed the appearance of two aromatic signals at about 8.74
and 8.55 as doublets (J = 2.5 Hz) for both compounds.

Synthesis of **6,7-Diethyl-1-methylpteridine-2,4-dione (40)** intermediate:

Compound **33** (200 mg, 1.27 mmol) was suspended in acetonitrile (5 mL) and 3,4-
hexanedione (185 µL, 1.52 mmol) was added. The mixture was heated at 70°C for 15
15 min with minimal product formation due to insolubility of **33**. Therefore DMF (3 mL)
and water (3 mL) were added and the temperature was raised to 100°C. After 90 min
total reaction time the mixture was cooled and poured into water (100 mL) and
extracted with ethyl acetate (3 x 75 mL). The organic layer was dried over MgSO₄
and evaporated to provide the colorless crystalline product. Yield 240 mg (81%); mp
20 218-222°C; ¹H NMR (DMSO-d₆) δ 11.78 (br s, 1H, NH), 3.46 (s, 3H, NCH₃), 2.95
and 2.93 (2q, 4H, 2CH₂ of ethyls), 1.28 and 1.23 (2t, 6H, 2CH₃ of ethyls). Analysis:
C₁₁H₁₄N₄O₂ (C, H, N; Table 2).

Synthesis of **1-Methyl-6-phenylpteridine-2,4-dione (42)** intermediate:

The nitrosopyrimidine **32** (220 mg, 1.28 mmol) was mixed thoroughly with phenethyl
25 amine hydrochloride (1.5 g, 9.5 mmol) and heated in an open beaker on the hot plate.
After a few minutes at about 160°C the purple reaction mixture fused to a brown paste.
TLC indicated many products so sulfolane (1 mL) was added and heat was continued
for 15 min. The reaction mixture was heated in water (10 mL) and then diluted 50

- mL in water and extracted with ethyl acetate (2 x 50 mL), the organic layer dried over MgSO_4 and then concentrated. The residue was flash chromatographed on silica gel using 4% MeOH in CH_2Cl_2 . Yield 75 mg (23%) of **42** as a pale yellow-orange solid. mp $>307^\circ\text{C}$ dec.; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 11.95 (br s, 1H, NH), 9.37 (s, 1H, C-7 H), 8.17 (m, 2H, 2',6' phenyl), 7.55 (m, 3H, 3',4',5' phenyl), 3.51 (s, 3H, NCH_3).
5 Anal. $\text{C}_{13}\text{H}_{10}\text{N}_4\text{O}_2$ (C, H, N).

EXAMPLE 12

SYNTHESIS OF COMPOUNDS 44, 47 AND 48

- General Method for Ring Closure of Pyrimidines to Thiadiazolo-pyrimidines
10 (Compounds 44-46):

- The orthodiamine **23**, **27**, or **32** (2.3 mmol) was suspended in dry acetonitrile (5 mL) and dry pyridine (1.5 mL) was added. Thionyl chloride (1 mL, 13.7 mmol) was added quickly and the mixture, which became clear and darkened, was heated at 60°C for 10 min. The mixture was then cooled and poured into 1N HCl (40 mL) with stirring.
15 The resulting yellow solution was extracted with ethyl acetate (3 x 40 mL), dried over MgSO_4 and evaporated to yield a pale yellow solid which was triturated with ether. Yield 65-74%.

Alkylation of these intermediates yielded the disubstituted products **47** and **48**.

EXAMPLE 13

SYNTHESIS OF COMPOUNDS 50 AND 52

- 20 Ethyl 4-[(2-methylamino)benzoyl]aminobutanoate (**51**):

- A mixture of N-methylisatoic anhydride (3.5 g, 19.8 mmol) was combined with 4-aminobutyric acid (2.5 g, 24.3 mmol) in dry DMF (50 mL) and heated at 100°C for 2 h. TLC indicated reaction to be complete and the DMF was removed in vacuo. The
25 residue was used directly for esterification which was accomplished by dissolving the residue in 100% ethanol (50 mL) and adding chlorotrimethyl silane (2.5 mL, 20 mmol). The mixture was heated at 65°C for 6 h and then evaporated to yield a brown

-41-

syrup. Crude yield 87% from isatoic anhydride. A small sample was purified for characterization and biological testing by preparative TLC using 7% MeOH in CH_2Cl_2 . The remainder of the material was used directly for preparation of compound 52. Analysis: $\text{C}_{14}\text{H}_{20}\text{N}_2\text{O}_3$ (C, H, N; Table 2).

5 Ethyl 1-Methyl-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinebutanoate (52):

The residue from 51 was combined with ethyl chloroformate (10 mL) and heated at 90°C for 1 h. The mixture was cooled and poured into saturated aqueous sodium bicarbonate (50 mL) with stirring and after 10 min extracted with ethyl acetate (2 x 75 mL). The organic layer was dried over MgSO_4 and evaporated to yield a brown
10 syrup. The crude product was flash chromatographed on silica using 3% MeOH in CH_2Cl_2 to yield g (%) of 52 as a thick oil. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.27-7.42 (2m, 4H, C-5,6,7,8), 4.04 (t, 2H, CH_2 of ethyl), 3.88 (m, 2H, NCH_2), 3.11 (s, 3H, NCH_3), 2.33 (t, 2H, 2' CH_2), 1.71 (m, 2H, 3' CH_2). Analysis: $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_4$ (C, H, N; Table 2).

-42-

TABLE 2**ANALYSIS OF SELECTED INVENTIVE COMPOUNDS AND INTERMEDIATES****(Combustion Elemental Analysis)**

5	4	Calc'd for $C_{11}H_{14}N_4O_4$: Found:	C, 49.62; H, 5.30; N, 21.04. C, 49.54; H, 5.31; N, 21.12.
10	5	Calc'd for $C_{12}H_{16}N_4O_4 + H^+$: Found:	HRMS 281.124980 281.123300
15	6	Calc'd for $C_{13}H_{18}N_4O_4$: Found:	C, 53.05; H, 6.16; N, 19.04. C, 52.79; H, 6.00; N, 18.99.
	7	Calc'd for $C_{14}H_{20}N_4O_4$: Found:	C, 54.54; H, 6.54; N, 18.17. C, 54.47; H, 6.42; N, 18.16.
20	8	Calc'd for $C_{16}H_{16}N_4O_4 \cdot 2/3 \text{ DMF}$: Found:	C, 57.29; H, 5.52; N, 17.33. C, 57.17; H, 5.51; N, 17.35.
25	10	Calc'd for $C_{15}H_{17}BrN_4O_4$: Found:	C, 41.84; H, 4.59; N, 15.01. C, 41.83; H, 4.43; N, 14.99.
	11	Calc'd for $C_{16}H_{15}BrN_4O_4$: Found:	C, 47.19; H, 3.71; N, 13.76. C, 47.02; H, 3.68; N, 13.63.
30	12	Calc'd for $C_{15}H_{18}N_4O_4S$: Found:	C, 47.84; H, 5.56; N, 17.17. C, 47.98; H, 5.44; N, 16.99.
35	13	Calc'd for $C_{17}H_{18}N_4O_4S$: Found:	C, 54.53; H, 4.85; N, 14.96. C, 54.41; H, 4.66; N, 14.72.
40	20	Calc'd for $C_{12}H_{20}N_4O_3$: Found:	C, 53.72; H, 7.51; N, 20.88. C, 54.00; H, 7.47; N, 20.65.

-43-

4	Calc'd for $C_{12}H_{18}N_4O_3$: Found:	C, 54.12; H, 6.81; N, 21.04. C, 54.23; H, 6.76; N, 21.04.
5	31 Calc'd for $C_{15}H_{22}N_4O_4$: Found:	C, 55.89; H, 6.88; N, 17.38. C, 55.67; H, 6.94; N, 17.22.
10	33 Calc'd for $C_7H_8N_4O_2$: Found:	C, 38.46; H, 5.16; N, 35.88. C, 38.22; H, 5.13; N, 35.84.
	34 Calc'd for $C_7H_8N_4O_2$: Found:	C, 47.19; H, 3.39; N, 31.45. C, 47.01; H, 3.18; N, 31.25.
15	35 Calc'd for $C_9H_{10}N_4O_2$: Found:	C, 52.42; H, 4.89; N, 27.17. C, 52.20; H, 4.74; H, 27.22.
20	36 Calc'd for $C_{13}H_{16}N_4O_4$: Found:	C, 53.42; H, 5.52; N, 19.17. C, 53.39; H, 5.43; N, 19.17.
	36a Calc'd for $C_{11}H_{12}N_4O_4$: Found:	C, 50.00; H, 4.58; N, 21.20. C, 49.92; H, 4.47; N, 21.26.
25	37 Calc'd for $C_{15}H_{20}N_4O_4$: Found:	C, 56.24; H, 6.29; N, 17.49. C, 56.04; H, 6.12; N, 17.42.
30	37a Calc'd for $C_{13}H_{16}N_4O_4 \cdot 4/5H_2O$: Found:	C, 50.91; H, 5.78; N, 18.27. C, 50.64; H, 5.81; N, 18.23.
	38 Calc'd for $C_{12}H_{12}N_4O_4 + H^+$: Found:	HRMS 277.093680 277.093800
35	39 Calc'd for $C_{17}H_{22}N_4O_6$: Found:	C, 53.96; H, 5.86; N, 14.81. C, 53.60; H, 5.73; N, 14.04.

40

-44-

40	Calc'd for $C_{11}H_{14}N_4O_2 \cdot 1/4H_2O$: Found:	C, 55.34; H, 6.12; N, 23.47. C, 55.37; H, 6.02; N, 23.43.
5	41 Calc'd for $C_{17}H_{24}N_4O_4$: Found:	C, 58.61; H, 6.94; N, 16.08. C, 59.22; H, 7.08; N, 15.69.
	41a Calc'd for $C_{15}H_{20}N_4O_4$: Found:	C, 56.24; H, 6.29; N, 17.49. C, 56.41; H, 6.27; N, 17.28.
10	42 Calc'd for $C_{13}H_{10}N_4O_2 \cdot 1/3H_2O$: Found:	C, 60.00; H, 4.13; N, 21.53. C, 59.78; H, 3.70; N, 21.14.
15	43 Calc'd for $C_{19}H_{20}N_4O_4 + H^+$: Found:	HRMS 369.156280 369.154800
	44 Calc'd for $C_{12}H_{18}N_4O_2S + H^+$: Found:	HRMS 283.122873 283.121300
20	45 Calc'd for $C_7H_4N_4O_2S$: Found:	C, 32.61; H, 2.19; N, 30.42. C, 32.65; H, 2.20; N, 30.29.
25	46 Calc'd for $C_7H_8N_4O_2S$: Found:	C, 39.62; H, 3.80; N, 26.40. C, 39.84; H, 3.60; N, 26.02.
	47 Calc'd for $C_{11}H_{14}N_4O_4S$: Found:	C, 44.29; H, 4.73; N, 18.78. C, 44.57; H, 4.67; N, 18.80.
30	47a Calc'd for $C_9H_{10}N_4O_4S + H^+$: Found:	HRMS 271.050102 271.050600
35	48 Calc'd for $C_{13}H_{18}N_4O_4$: Found:	C, 47.84; H, 5.56; N, 17.17. C, 47.97; H, 5.66; N, 17.08.

40

-45-

51	Calc'd for $C_{14}H_{20}N_2O_3 \cdot 1/2H_2O$: Found:	C, 61.52; H, 7.74; N, 10.25. C, 61.54; H, 7.44; N, 9.77.
5 52	Calc'd for $C_{15}H_{18}N_2O_4 \cdot CH_3OH$: Found:	C, 59.62; H, 6.88; N, 8.69. C, 60.61; H, 6.84; N, 8.58.
52a	Calc'd for $C_{13}H_{14}N_2O_4$: Found:	C, 59.54; H, 5.38; N, 10.68. C, 59.55; H, 5.32; N, 10.59.
10		


5

The invention having been fully described, modifications thereof may be apparent to those of ordinary skill in the art. Such modifications are within the scope of the
10 invention as defined by the appended claims.

-47-

CLAIMS

1. A compound having the formula:



wherein Z is N or CH;

R_1 is $(CH_2)_nA$, where:

- 5 A is NH_2 , acyloxy, SO_3H , PO_4H_2 , $NNO(OH)$, SO_2NH_2 , $PO(OH)NH_2$, SO_2R or $COOR$ where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

- 10 n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages;


- 15 and, preferably, R_1 is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above);

R_2 is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a ω -hydroxyalkyl having from 1 to 7 carbon atoms;

R_3 is the same as R_2 ; and,

- 20 X is H, any halogen, OH, SH, OR' , or SR' , where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 4 carbon atoms.

2. A compound according to Claim 1 wherein $n=3$, $A=\text{COOEt}$, $R_2=\text{Me}$, $X=\text{H}$ and $Z=\text{N}$.
3. A compound according to Claim 1 wherein $n=4$, $A=\text{COOEt}$, $R_2=\text{Me}$, $X=\text{H}$ and $Z=\text{N}$.
- 5 4. A compound according to Claim 1 wherein $R_1=\omega$ -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A.
5. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 1 and a physiologically acceptable carrier.
- 10 6. A compound having the formula:



R_1 is $(\text{CH}_2)_n\text{A}$, where:

A is NH_2 , acyloxy, SO_3H , PO_4H_2 , $\text{NNO}(\text{OH})$, SO_2NH_2 , $\text{PO}(\text{OH})\text{NH}_2$, SO_2R or COOR where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages;

-49-

and, preferably, R_1 is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above);

R_2 is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a ω -hydroxyalkyl having from 1 to 7 carbon atoms;

R_4 is the same as R_2 , OH or an O-alkyl having from 1 to 5 carbon atoms;

R_5 is the same as R_2 , OH or an O-alkyl having from 1 to 5 carbon atoms; and,


Z is N or CH.

10 7. A compound according to Claim 6 wherein $n=3$, $A=COOEt$, $R_2=MeCH_2CH_2$ (normal) and both R_4 and $R_5=H$.

8. A compound according to Claim 6 wherein $R_1=\omega$ -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A.

15 9. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 6 and a physiologically acceptable carrier.

10. A compound having the formula:



R_1 is $(CH_2)_nA$, where:

5

A is NH_2 , acyloxy, SO_3H , PO_4H_2 , $NNO(OH)$, SO_2NH_2 , $PO(OH)NH_2$, SO_2R or $COOR$ where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

10

n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages;

and, preferably, R_1 is a ω -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above); and

15

R_2 is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a ω -hydroxyalkyl having from 1 to 7 carbon atoms.

11. A compound according to Claim 10 wherein $n=3$, $A=COOEt$ and $R_2=MeCH_2$, CH_2 .


12. A compound according to Claim 10 wherein $R_1=\omega$ -carboxyalkyl, ω -carboxyalkenyl, or ω -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A.

20

13. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 10 and a physiologically acceptable carrier.

-51-

14. A compound having the formula:



R_2 is $(CH_2)_nA$, where:

5

A is H, NH_2 , acyloxy, SO_3H , PO_4H_2 , $NNO(OH)$, SO_2NH_2 , $PO(OH)NH_2$, SO_2R or $COOR$ where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl;

10

n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form respectively, ether or amino linkages;

and, preferably, R_2 is a ϕ -carboxyalkyl, ϕ -carboxyalkenyl, or ϕ -carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above); and

15

R_3 is H, an alkyl, or a ϕ -hydroxyalkyl having from 1 to 7 carbon atoms;

R_4 is H, OH, NH_2 or O-alkyl having from 1-7 carbon atoms;

R_6 is H, OH, NO, NO_2 , NH_2 , an O-alkyl having from 1-7 carbon atoms, or X where:

where X is H, any halogen, OH, SH, OR' , or SR' , where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 7 carbon atoms; and,

R₇ is H, OH, NO, NO₂, NH₂, an O-alkyl having from 1-7 carbon atoms, or X where:

where X is H, any halogen, OH, SH, OR', or SR', where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 7 carbon atoms.

- 5 15. The compound according to Claim 14 wherein R₂ = COOR and R is Et;
R₃
and R₄ = H; and, R₆ and R₇ = O·CH₃.
16. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 14 and a physiologically acceptable carrier.
- 10 17. A method for use of a pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 1 in a physiologically acceptable carrier, wherein the method comprises administering the compound to a host in an amount and for a time sufficient to provide protection to the host against a ceramide associated condition being experienced in a tissue of the host.
- 15 18. A method for use of a pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 6 in a physiologically acceptable carrier, wherein the method comprises administering the compound to a host in an amount and for a time sufficient to provide protection to the host against a ceramide associated condition being experienced in a tissue of the host.
- 20 19. A method for use of a pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 10 in a physiologically acceptable carrier, wherein the method comprises administering the compound to a host in an amount and for a time sufficient to induce recovery by the host against a ceramide associated condition being experienced in a tissue of the host.

-53-

20. A method for use of a pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 13 in a physiologically acceptable carrier, wherein the method comprises administering the compound to a host in an amount and for a time sufficient to provide protection to the host against a
5 ceramide associated condition being experienced in a tissue of the host.
21. The method according to Claim 17 wherein the ceramide associated condition is inflammation.
22. The method according to Claim 18 wherein the ceramide associated condition is inflammation.
- 10 23. The method according to Claim 19 wherein the ceramide associated condition is inflammation.
24. The method according to Claim 20 wherein the ceramide associated condition is inflammation.
25. The method according to Claim 18 wherein the ceramide associated
15 condition is fibrosis.
26. The method according to Claim 18 wherein the ceramide associated condition is fibrosis.
27. The method according to Claim 19 wherein the ceramide associated condition is fibrosis.
- 20 28. The method according to Claim 20 wherein the ceramide associated condition is inflammation.
29. The method according to Claim 17 wherein the ceramide associated condition is cell senescence or apoptosis.

30. The method according to Claim 18 wherein the ceramide associated condition is cell senescence or apoptosis.
31. The method according to Claim 19 wherein the ceramide associated condition is cell senescence or apoptosis.
- 5 32. The method according to Claim 20 wherein the ceramide associated condition is cell senescence or apoptosis.
33. The method according to Claim 29 wherein the ceramide associated condition is radiation dermatitis, sunburn or UV induced immune suppression in skin.
34. The method according to Claim 30 wherein the ceramide associated
10 condition is radiation dermatitis, sunburn or UV induced immune suppression in skin.
35. The method according to Claim 31 wherein the ceramide associated condition is radiation dermatitis, sunburn or UV induced immune suppression in skin.
36. The method according to Claim 33 wherein the ceramide associated condition is radiation dermatitis, sunburn or UV induced immune suppression in skin.

1/14




FIG. 1





FIG. 2

SUBSTITUTE SHEET (RULE 26)

FIG. 3



3/14

FIG. 4(A)




FIG. 4(B)





FIG. 4(C)



SUBSTITUTE SHEET (RULE 26)

4/14

FIG. 4(D)




FIG. 4(E)





FIG. 4(F)



SUBSTITUTE SHEET (RULE 26)

5/14

FIG. 4(G)





FIG. 6

INHIBITION OF TYPE IU PHOSPHODIESTERASE



SUBSTITUTE SHEET (RULE 26)

FIG. 5(a)





FIG. 5(b)



7/14

FIG. 7





FIG. 10



SUBSTITUTE SHEET (RULE 26)

8/14




FIG. 8

SUBSTITUTE SHEET (RULE 26)

9/14




FIG. 9

SUBSTITUTE SHEET (RULE 26)

10/14

FIG. 11






FIG. 12



SUBSTITUTE SHEET (RULE 26)

11/14


FIG. 13




SUBSTITUTE SHEET (RULE 26)

12/14


S45,928-3
3-NITROIXOCARBOSTYRIL
 $C_9H_6N_2O_3$




S76,334-9
N2DIMETHYL-3-(3-FLUOROPHENYL)-1-OXO-1234
TETRAHYDRO-4-ISOQUINOLINECARBOXAMIDE
 $C_{18}H_{17}FN_2O_2$




S93,63C-8
3-AMINO-CYANO-7-NITRO-2-PHENYL-1(2H)-
ISOQUINOLONE
 $C_{15}H_{10}N_4O_3$




S76,469-8
2-METHYL-3-(2-OXOPROPYL)-1(2H)-ISOQUINOLINE
CNE
 $C_{13}H_{13}NO_2$



S88,370-0
2-(2-HYDROXYETHYL)-1,4-(2H,3H)-ISOQUINOLONE
 $C_{11}H_{11}NO_3$



21,493-0
(H)-1234 TETRAHYDRO-3-ISOQUINOLINE
CARBOXYLIC ACID HYDROCHLORIDE
 $C_{10}H_{11}NO_2$



*HC

FIG. 14(A)


SUBSTITUTE SHEET (RULE 26)

13/14


FIG. 14(B)

36,895-4

3-HYDROXYISOQUINOLINE, 99%


 C_9H_7NO 

S94,009-7

3-AMINO-4-CYANO-2-HEXYL-7-NITRO-1(2H)-
ISOQUINOLONE $C_{16}H_{18}N_4O_3$ 


S75,699-7

2-BROMO-4-NITRO-6(5H)-PHENANTHRIDINONE

 $C_{13}H_7BrN_2O_3$ 


S52,626-6

6,7-DIMETHOXY-1(2H)-ISOQUINOLONE

 $C_{11}H_{11}NO_3$ 


S84,100-5

4-ISOQUINOLINECARBOXYLIC ACID

 $C_{10}H_7NO_2$ 

15,013-4


1-ISOQUINOLINECARBOXYLIC ACID, 99%

 $C_{10}H_7NO_2$ 


SUBSTITUTE SHEET (RULE 26)

14/14

S76,087-0
2-(2-(3,4-DIMETHOXYPHENYL)ETHYL)ISOQUINOLINE-1,3
(2H,4H)-DIONE
 $C_{19}H_{19}NO_4$



S76,473-6
1,2-DIHYDRO-2-METHYL-1-OXO-3-ISOQUINOLINES
UTYRIC ACID
 $C_{14}H_{15}NO_3$



29,963-4
5(5H)-PHENANTHRIDINONE
 $C_{13}H_9NO$






FIG. 14(C)

N165-8
1,8-NAPHTHALIMIDE, 99%
 $C_{12}H_7NO_2$



33,854-0
3-ISOQUINOLINECARBOXYLIC ACID HYDRATE, 99%
 $C_{10}H_7NO_2$



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JS95/16521

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/52; C07D 473/10, 473/04

US CL : 544/266, 270, 271, 272, 273, 276; 514/262, 265

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 544/266, 270, 271, 272, 273, 276; 514/262, 265

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEMICAL ABSTRACTS ON LINE THROUGH STN BASED ON CHEMICAL STRUCTURE OF CLAIM 1 WHERE Z IS N.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	WO, A, 92/21344 (FRED HUTCHINSON CANCER RESEARCH CENTER) 10 December 1992, see claims 6 and 10.	1, 2, 3, 4, 5, (in part where Z is N) and 17
A	US, A, 5,366,978 (FURUKAWA ET AL.) 22 November 1994, see claim 1.	1-5 (in part where Z is N) and 17
A	US, A, 5,288,721 (KLEIN ET AL.) 22 February 1994, see claims 1 and 10.	1-5 (in part where Z is N) and 17

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 MAY 1996

Date of mailing of the international search report

10 MAY 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

JOHN M. FORD

Telephone No. (703) 308-1235

Facsimile No. (703) 305-3230

Form PCT/ISA/210 (second sheet)(July 1992)*

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim 1, where Z is N, which are purines in 544/264 with which claims 2 and 3 join.

Group II, claim 1 where Z is CH, bicyclic pyrimidines in 544/280.

Group III, claims 6, 7, 8, 9, 15, 18, 22, 25, 26, 30 to 34. Pteridines in 544/257.

Group IV, claims 10, 11, 12, and 13, 16, 20, 23, 24, 27, 28, 31, 32, and 35. Bicyclic compounds, pyrimidine fused to a thiadiazole in 544/254.

Group V, claims 14, 15, and 16, drawn to isoquinolinones, in Class 546, various subclasses.

Claims 4, 5, 17, 21, 29, 33, and 36 will be examined with either Group I or Group II, to the extent elected.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

These distinct inventions have acquired separate status in the art as evidenced by distinct core structures, will support separate patents, and are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.